Safe & Easy for Alzheimer's Disease and Related Pathologies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-06-30

Study Completion Date

2017-03-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

All over the world the increasing prevalence of chronic disorders and its impact on functional decline is challenging the sustainability of health care systems. Older individuals also frequently experience the reversible "frailty syndrome", which overlaps with chronic diseases, increasing incidence of disability.

Building a global system aiming to take in charge all causes leading to loss of autonomy is a rather complicated task involving numerous Information and Communication technologies (ICT) solutions which are not always easy to use in everyday life.

The SafEE (Safe Easy Environment) project aim is to improve the safety, autonomy and quality of life of older people at risk.

The SafEE2 project develop non pharmacological therapeutic through diferent ICT (stimulation aromatherapy automatic fragrance ...) .

The goal of this study is to validate the acceptability, sensitivity and efficacy of the systems.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safe & Easy Environment at Home for Patients Presenting a Frail Syndrome

NCT02288221

Cognitive Deterioration

TERMINATED NA

Patients With Alzheimer's Disease or Related Youth Disease

NCT03508024

Alzheimer Disease, Early Onset Lewy Body Disease Frontotemporal Lobar Degeneration

COMPLETED

Impact of Controlling Vascular Risk Factors on the Progression of Alzheimer's Disease

NCT01423396

Alzheimer's Disease Cardiovascular Risk Factors

COMPLETED NA

Auditory Rehabilitation and Cognition in Alzheimer Patients

NCT03002142

Alzheimer's Disease Hearing Loss

COMPLETED NA

Pharmaceutical Collaborative Care Integrated to a Multidisciplinary Psychosocial Program

NCT02802371

Alzheimer Disease

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The non pharmacological therapeutic will be install at hospital room :

* aromatherapy,
* music therapy,
* cognitive training in multimedia application offering cognitive games.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cognitive Deterioration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Alzheimer's Disease

Group Type EXPERIMENTAL

Patient's answer with non pharmacological therapeutic

Intervention Type OTHER

Installation at patient's home of :

* aromatherapy
* music therapy
* cognitive training in multimedia application offering cognitive games

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Patient's answer with non pharmacological therapeutic

Installation at patient's home of :

* aromatherapy
* music therapy
* cognitive training in multimedia application offering cognitive games

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects with a diagnosis of Alzheimer's disease according to NINCDS-ADRDA (McKhann, Drachman et al. 1984) or typical or atypical Alzheimer's disease (Dubois B. et al. 2007).
* Score at Mini Mental Test (MMSE) ≥16.
* Subjects residing in nursing homes.
* Subjects beneficiaries of a social security scheme.
* Signature of free and informed consent.

Exclusion Criteria

* Failure to pass the neuropsychological tests because of a sensory or motor deficit.
* Sensory deficit (olfactory or visual) preventing the patient made perfectly meet the therapeutic solutions.
* Prescription of a new treatment psychotropic (hypnotic, anxiolytic, antidepressant, antipsychotic) in the week before the evaluation;
* Persons deprived of liberty (administrative or judicial).

Minimum Eligible Age

60 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No